What changed
Nine-month figures are steadier. Cumulative revenue rose 11.3% to 1 trillion 151.7 billion won. Operating profit rose 14.8% to 181.4 billion won, and net income grew 25.3% to 151.9 billion won.
Nabota, the botulinum toxin, did the heavy lifting. Its Q3 revenue hit 116.3 billion won, a quarterly record for the product. Exports were 106.8 billion won, up 127.9%. The report says U.S. distributor Evolus pulled U.S.-bound inventory forward into the third quarter ahead of a September tariff implementation. That is a timing story as much as a demand story.
Digital healthcare revenue rose 40% to 17.9 billion won. The over-the-counter division, 13% of total sales, grew 21%, helped by Urokinase and health functional foods.
Pexcluu, the new gastroesophageal reflux drug, went the other way. Revenue slipped slightly after joint marketing with Chong Kun Dang ended. A Daewoong official called the dip temporary, tied to the move to direct sales. Securities analysts estimated Pexcluu's Q3 revenue at about 3 billion won.
What it means for practices (our read)
Look at the export line before you read the profit line. A 127.9% export jump on a single quarter, driven by a distributor front-loading stock before a tariff date, does not tell an owner how U.S. demand is trending. It tells you a wholesaler's warehouse was full in September. Expect a softer fourth quarter.
Sangsangin Securities analyst Lee Dal-mi expects exactly that. She said orders may fall in Q4 and leave an order gap until Q1 next year. In her view Pexcluu will partly cover that gap, and Nabota sales should rebound in the first half of 2027. She also argued the gap could close sooner if Evolus expands sales into Europe and Canada, which the report says is planned.
The company's own remarks point at the North American plant. A company official said cGMP certification for the new plant is expected in 2027, and that it would support larger commercial production. Until that plant is certified, U.S. supply capacity is the constraint to watch, not demand alone.
What owners can do
Pull your own purchasing history for Nabota and any other Daewoong product before Q4 and compare it with the Q3 pattern. If your practice bought ahead of the tariff date, expect thinner allocations or slower reorders in the next quarter. If you have not bought in the last two quarters, ask your distributor directly about current stock levels and any change in lead times. Confirm with your supplier how any tariff cost is passed through on invoices, because the report does not say how pricing moves for end buyers.
What we don't know yet
The 76.8 billion won operating profit is provisional, and the report does not say whether final numbers will change. The article does not give Nabota's U.S. price, unit volumes, or the size of the Q4 order gap. It also does not name the tariff rate or the exact date it took effect. The new plant's cGMP timeline is a company statement, and the report gives no third-party confirmation of it. The article is an AI-assisted translation of a Korean original, and the report itself warns that details may differ, so check the Korean source before relying on any single figure.
Business information, not medical or legal advice. Verify regulatory status at FDA.gov.